Inovio to begin rolling submission of bla for ino-3107 for the treatment of rrp in adults

Complete submission of the biologics license application (bla) remains on track for 2h25 with the goal of file acceptance by u.s. food and drug administration (fda) by end of 2025 plymouth meeting, pa. , aug. 26, 2025 /prnewswire/ -- inovio (nasdaq: ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from hpv-related diseases, cancer, and infectious diseases, today announced that the fda has notified inovio that it agrees with its rolling submission timeline for the bla for ino-3107 as a treatment for adults with recurrent respiratory papillomatosis (rrp.
INO Ratings Summary
INO Quant Ranking